【摘要】 目的:比较肝癌及良性肝病患者血清中miRNA-183的表达并探讨其临床意义。方法:收集肝癌患者血清标本54例,肝硬化患者血清标本45例,肝炎患者血清标本30例及健康体检者血清标本45例,荧光定量PCR检测miRNA-183在各组中的表达量及分析肝癌组与临床病理特征之间的关系。结果:肝癌患者血清中miR-183表达量高于正常对照组,也高于肝炎组及肝硬化组(P<0.05);肝硬化组血清miR-183表达量高于正常对照组(P<0.05)。肝癌患者的血清miR-183表达量与TNM分期有关,Ⅲ~Ⅳ期的表达水平高于Ⅰ~Ⅱ期(P<0.05);低分化肝癌患者血清miR-183的表达水平高于高-中分化患者(P<0.05);伴有肝硬化的肝癌患者其血清miR-183表达水平高于不伴肝硬化者(P<0.05)。ROC曲线下面积为0.699(95%CI 0.613~0.784),最佳临界值为1.38,相应的敏感性为53.7%,特异性为83.3%,阳性预测值为60.1%,阴性预测值为76.9%。结论:血清miR-183可能作为诊断肝癌的新型肿瘤标志物,并可能预测肝癌预后。更多还原

【Abstract】 Objective: To compare the expression of serum miR-183 in hepatocellular carcinoma(HCC) and benign liver diseases and explore its clinical significance. Methods: Serum miR-183 expression was measured in HCC(n =54), liver cirrhosis(LC)(n =45),chronic viral hepatitis(CH)(n =30) and normal controls(NC)(n =45) by quantitative real-time reverse-transcription polymerase chain reaction(qRTPCR). Results: The expression of serum miR-183 in HCC was higher than those in normal controls, hepatitis and cirrhosis patients(P <0.05); the expression of serum miR-183 in cirrhosis patients was also higher than that in normal controls(P <0.05). The expression of serum miR-183 was higher in Ⅲ~Ⅳ stage than that in Ⅰ~Ⅱ stage in HCC(P <0.05); well-differentiated HCC was lower than that in poor-differentiated HCC(P<0.05); and HCC patients with cirrhosis had a higher expression of miR-183 than those without cirrhosis. ROC curve of serum miR-183 in HCC had an ideal diagnostic value, with a optimal value of 1.38; the diagnostic sensitivity and specificity were 53.7%and 83.3%, respectively and the positive predictive value and negative predictive value were 60.1%, 76.9%,respectively. Conclusion:Serum miR-183 may act as a new tumor marker and may predict the prognosis and therapeutic effect.更多还原